ROIV 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
ROIV 近期報酬表現
0.45%
Roivant sciences ltd
0.71%
同產業平均
-0.02%
S&P500
與 ROIV 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
ABUS | Arbutus biopharma corp | 4 分 | 5 分 | 3 分 | 3 分 | 1 分 | |
TSBX | Turnstone biologics corp | - | 3 分 | 4 分 | 1 分 | 1 分 | |
DTIL | Precision biosciences inc | 4 分 | 2 分 | 4 分 | 1 分 | 1 分 | |
INBX | Inhibrx inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
ABCL | Abcellera biologics inc | 4 分 | 1 分 | 2 分 | 2 分 | 1 分 |
- ABUS Arbutus biopharma corp價值 4 分趨勢 5 分波段 3 分籌碼 3 分股利 1 分查看更多
ROIV 公司資訊
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company's pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn's disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.